acellular tissue engineered vessel-tyod (symvess)
acellular tissue engineered vessel-tyod is an FDA-licensed reference biologic from Humacyte Global Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2024
Reference approved
Reference product
symvess acellular tissue engineered vessel-tyod
Humacyte Global Inc.
- Approved
- Dec 19, 2024
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for acellular tissue engineered vessel-tyod, in chronological order.
First licensure
Date acellular tissue engineered vessel-tyod was first licensed by the FDA.
1 yr 6 mo ago
Reference approval
Approval date of the reference acellular tissue engineered vessel-tyod product.
1 yr 6 mo ago
Reference exclusivity ends
12-year reference-product exclusivity under the BPCIA.
in 10 yr 8 mo
Frequently asked questions
Are there biosimilars approved for acellular tissue engineered vessel-tyod (symvess)?
No 351(k) biosimilars or interchangeable biosimilars referencing acellular tissue engineered vessel-tyod are listed in the FDA Purple Book yet.
When does acellular tissue engineered vessel-tyod (symvess) lose reference-product exclusivity?
acellular tissue engineered vessel-tyod's 12-year reference-product exclusivity under the BPCIA is listed in the FDA Purple Book as ending December 19, 2036.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.